Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Nature Reviews. Cancer
|
April 14, 2026
The versatile interplay between steatotic liver disease and liver cancer
Mohammad Rahbari, Albert Gris-Oliver, Pierluigi Ramadori, et al.
Genome Medicine
|
September 10, 2020
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
Lidia Mateo, Miquel Duran-Frigola, Albert Gris-Oliver, et al.
Elife
|
September 2, 2021
Ascorbic acid supports ex vivo generation of plasmacytoid dendritic cells from circulating hematopoietic stem cells
Anders Laustsen, Renée M van der Sluis, Albert Gris-Oliver, et al.
Cancers
|
May 28, 2022
GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells
Chiara Bellio, Marta Emperador, Pol Castellano, et al.
Molecular Oncology
|
December 8, 2025
Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib
Ugne Balaseviciute, Júlia Huguet-Pradell, Jordi Abril-Fornaguera, et al.
JHEP Reports : Innovation in Hepatology
|
December 1, 2025
Artificial intelligence predicts outcome-related molecular profiles and vascular invasion in hepatocellular carcinoma
Tobias Paul Seraphin, Agavni Mesropian, Laura Žigutytė, et al.
Cell Reports
|
March 12, 2025
Distinctive CD8<sup>+</sup> T cell activation by antigen-presenting plasmacytoid dendritic cells compared to conventional dendritic cells
Renée M van der Sluis, Juan L García-Rodríguez, Ian Helstrup Nielsen, et al.
Oncogene
|
October 14, 2022
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
Shanade Dunn, Cath Eberlein, Jason Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2015
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
Celina García-García, Martín A Rivas, Yasir H Ibrahim, et al.
British Journal of Cancer
|
March 16, 2021
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer
Albert Gris-Oliver, Yasir H Ibrahim, Martín A Rivas, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Nature Reviews. Cancer
|
April 14, 2026
The versatile interplay between steatotic liver disease and liver cancer
Mohammad Rahbari, Albert Gris-Oliver, Pierluigi Ramadori, et al.
Genome Medicine
|
September 10, 2020
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
Lidia Mateo, Miquel Duran-Frigola, Albert Gris-Oliver, et al.
Elife
|
September 2, 2021
Ascorbic acid supports ex vivo generation of plasmacytoid dendritic cells from circulating hematopoietic stem cells
Anders Laustsen, Renée M van der Sluis, Albert Gris-Oliver, et al.
Cancers
|
May 28, 2022
GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells
Chiara Bellio, Marta Emperador, Pol Castellano, et al.
Molecular Oncology
|
December 8, 2025
Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib
Ugne Balaseviciute, Júlia Huguet-Pradell, Jordi Abril-Fornaguera, et al.
JHEP Reports : Innovation in Hepatology
|
December 1, 2025
Artificial intelligence predicts outcome-related molecular profiles and vascular invasion in hepatocellular carcinoma
Tobias Paul Seraphin, Agavni Mesropian, Laura Žigutytė, et al.
Cell Reports
|
March 12, 2025
Distinctive CD8<sup>+</sup> T cell activation by antigen-presenting plasmacytoid dendritic cells compared to conventional dendritic cells
Renée M van der Sluis, Juan L García-Rodríguez, Ian Helstrup Nielsen, et al.
Oncogene
|
October 14, 2022
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
Shanade Dunn, Cath Eberlein, Jason Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2015
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
Celina García-García, Martín A Rivas, Yasir H Ibrahim, et al.
British Journal of Cancer
|
March 16, 2021
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer
Albert Gris-Oliver, Yasir H Ibrahim, Martín A Rivas, et al.
Page
of 3